Compare Toronto-Dominion Bank (TD) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs 10X Genomics Inc — how do they compare? Toronto-Dominion Bank trades at $114.14 (market cap $186.61B), while 10X Genomics Inc trades at $79.3 (market cap $9.92B). The key difference: Toronto-Dominion Bank is far larger — about 18.8× 10X Genomics Inc's market cap, and Toronto-Dominion Bank pays a 2.84% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Toronto-Dominion Bank for 84 Days and 10X Genomics Inc for 92 Days on average.
| TD | TXG | |
|---|---|---|
Market Cap | $186.61B | $9.92B |
Volume | 4,056,663 | 9,372,166 |
Sector | Financials | Health |
52-Week High | $124.80 | $97.74 |
52-Week Low | $78.32 | $11.48 |
Typical Hold Time | 84 Days | 92 Days |
Enterprise Value | $559.39B | $9.44B |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TD stock trades at $114.04, down 3.5% today, with a bearish technical signal. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.98 versus $1.74 expected. The company announced a $10 billion share buyback program and is expanding its U.S. branch network. Revenue grew to $61.28 billion in 2025, with a net income margin of 24.88%.
The outlook is mixed: strong profitability and analyst buy ratings support upside, but bearish technicals and volatile cash flows pose risks. The stock's valuation appears reasonable with a P/E of 17.39. Key risks include execution of expansion plans and macroeconomic sensitivity.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
